IBDEI1Z0 ; ; 20-MAY-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;OCT 15, 2014
 Q:'DIFQR(358.4)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.4,559,0)
 ;;=GLAUCOMA^3^49
 ;;^UTILITY(U,$J,358.4,560,0)
 ;;=STRABISMUS^11^49
 ;;^UTILITY(U,$J,358.4,561,0)
 ;;=INFECTIONS/INFLAMMATION/CONJUNCTIVA^4^49
 ;;^UTILITY(U,$J,358.4,562,0)
 ;;=MOST COMMON^1^49
 ;;^UTILITY(U,$J,358.4,563,0)
 ;;=LEGALLY BLIND^5^49
 ;;^UTILITY(U,$J,358.4,564,0)
 ;;=NEW PATIENT^3^50
 ;;^UTILITY(U,$J,358.4,565,0)
 ;;=ESTABLISHED PATIENT^2^50
 ;;^UTILITY(U,$J,358.4,566,0)
 ;;=CONSULTATIONS^4^50
 ;;^UTILITY(U,$J,358.4,567,0)
 ;;=EYE CODES^1^50
 ;;^UTILITY(U,$J,358.4,568,0)
 ;;=REFRACTION^7^51
 ;;^UTILITY(U,$J,358.4,569,0)
 ;;=GLASSES/CONTACT LENSES^2^51
 ;;^UTILITY(U,$J,358.4,570,0)
 ;;=SPECIAL OPHTHALMIC SERVICES^9^51
 ;;^UTILITY(U,$J,358.4,571,0)
 ;;=PROCEDURES^6^51
 ;;^UTILITY(U,$J,358.4,572,0)
 ;;=LASER PROCEDURES^4^51
 ;;^UTILITY(U,$J,358.4,573,0)
 ;;=RETINA PROCEDURES^8^51
 ;;^UTILITY(U,$J,358.4,574,0)
 ;;=MEDICATIONS^5^51
 ;;^UTILITY(U,$J,358.4,575,0)
 ;;=INTRAVITREAL INJECTIONS^3^51
 ;;^UTILITY(U,$J,358.4,576,0)
 ;;=EDUCATION/COUNSELING^1^51
 ;;^UTILITY(U,$J,358.4,577,0)
 ;;=ORBIT/EYELID/LACRIMAL^9^52
 ;;^UTILITY(U,$J,358.4,578,0)
 ;;=ANTERIOR SEGMENT/LACRIMAL^2^52
 ;;^UTILITY(U,$J,358.4,579,0)
 ;;=LENS/CATARACT^6^52
 ;;^UTILITY(U,$J,358.4,580,0)
 ;;=RETINA/VITREOUS/CHOROID^10^52
 ;;^UTILITY(U,$J,358.4,581,0)
 ;;=NEUROLOGIC EYE DISEASE^8^52
 ;;^UTILITY(U,$J,358.4,582,0)
 ;;=MEDICAL/SYSTEMIC/TRAUMA/OTHER^7^52
 ;;^UTILITY(U,$J,358.4,583,0)
 ;;=GLAUCOMA^3^52
 ;;^UTILITY(U,$J,358.4,584,0)
 ;;=STRABISMUS^11^52
 ;;^UTILITY(U,$J,358.4,585,0)
 ;;=INFECTIONS/INFLAMMATION/CONJUNCTIVA^4^52
 ;;^UTILITY(U,$J,358.4,586,0)
 ;;=MOST COMMON^1^52
 ;;^UTILITY(U,$J,358.4,587,0)
 ;;=LEGALLY BLIND^5^52
 ;;^UTILITY(U,$J,358.4,588,0)
 ;;=NEW PATIENT^2^53
 ;;^UTILITY(U,$J,358.4,589,0)
 ;;=ESTABLISHED PATIENT^1^53
 ;;^UTILITY(U,$J,358.4,590,0)
 ;;=CONSULTATIONS^3^53
 ;;^UTILITY(U,$J,358.4,591,0)
 ;;=BIOPSY/DEBRIDEMENT^1^54
 ;;^UTILITY(U,$J,358.4,592,0)
 ;;=I&D/ASPIRATION^4^54
 ;;^UTILITY(U,$J,358.4,593,0)
 ;;=DESTRUCT-BENIGN/PREMALIG LESIONS^2^54
 ;;^UTILITY(U,$J,358.4,594,0)
 ;;=SCOPES^7^54
 ;;^UTILITY(U,$J,358.4,595,0)
 ;;=EXCISION^3^54
 ;;^UTILITY(U,$J,358.4,596,0)
 ;;=MISCELLANEOUS^5^54
 ;;^UTILITY(U,$J,358.4,597,0)
 ;;=PEG TUBE^6^54
 ;;^UTILITY(U,$J,358.4,598,0)
 ;;=UNNA BOOT^8^54
 ;;^UTILITY(U,$J,358.4,599,0)
 ;;=WOUND VAC DRESSING^9^54
 ;;^UTILITY(U,$J,358.4,600,0)
 ;;=POST-OP COMPLICATIONS^17^55
 ;;^UTILITY(U,$J,358.4,601,0)
 ;;=GENERAL/SIGNS & SYMPTOMS^6^55
 ;;^UTILITY(U,$J,358.4,602,0)
 ;;=GYN/BREAST^8^55
 ;;^UTILITY(U,$J,358.4,603,0)
 ;;=MALE BREAST^10^55
 ;;^UTILITY(U,$J,358.4,604,0)
 ;;=BENIGN LESIONS OF SKIN^3^55
 ;;^UTILITY(U,$J,358.4,605,0)
 ;;=MALIGNANT LESIONS OF SKIN^11^55
 ;;^UTILITY(U,$J,358.4,606,0)
 ;;=MELANOMA^12^55
 ;;^UTILITY(U,$J,358.4,607,0)
 ;;=LACERATIONS^9^55
 ;;^UTILITY(U,$J,358.4,608,0)
 ;;=MERKEL CELL CANCER^13^55
 ;;^UTILITY(U,$J,358.4,609,0)
 ;;=AFTERCARE POST SURGERY^2^55
 ;;^UTILITY(U,$J,358.4,610,0)
 ;;=CARDIOVASCULAR^4^55
 ;;^UTILITY(U,$J,358.4,611,0)
 ;;=ENT^5^55
 ;;^UTILITY(U,$J,358.4,612,0)
 ;;=ABDOMINAL PAIN^1^55
 ;;^UTILITY(U,$J,358.4,613,0)
 ;;=GI^7^55
 ;;^UTILITY(U,$J,358.4,614,0)
 ;;=RESPIRATORY^19^55
 ;;^UTILITY(U,$J,358.4,615,0)
 ;;=ORTHOPEDIC^15^55
 ;;^UTILITY(U,$J,358.4,616,0)
 ;;=PLASTIC SURGERY^16^55
 ;;^UTILITY(U,$J,358.4,617,0)
 ;;=UROLOGY^20^55
 ;;^UTILITY(U,$J,358.4,618,0)
 ;;=PRE-OP EXAM^18^55
 ;;^UTILITY(U,$J,358.4,619,0)
 ;;=METASTATIC CANCER SITES^14^55
 ;;^UTILITY(U,$J,358.4,620,0)
 ;;=NEW PATIENT^2^56
 ;;^UTILITY(U,$J,358.4,621,0)
 ;;=ESTABLISHED PATIENT^1^56
 ;;^UTILITY(U,$J,358.4,622,0)
 ;;=CONSULTATIONS^3^56
 ;;^UTILITY(U,$J,358.4,623,0)
 ;;=COMPREHENSIVE ASSESSMENT/TREATMENT^2^57
